Operative Management of Atypical Femur Fractures

Atticus Coscia¹, Jenna Wilson¹, Stefano Muscatelli¹, Mark Hake^{1

2}

Affiliations

¹ Department of Orthopaedic Surgery, University of Michigan Hospital, Ann Arbor, MI; and.
² Trinity Health Ann Arbor, Ann Arbor, MI.

Atticus Coscia et al. J Orthop Trauma. 2024.

. 2024 Aug 1;38(8S):S7-S8.

doi: 10.1097/BOT.0000000000002834.

Atticus Coscia¹, Jenna Wilson¹, Stefano Muscatelli¹, Mark Hake^{1

2}

¹ Department of Orthopaedic Surgery, University of Michigan Hospital, Ann Arbor, MI; and.
² Trinity Health Ann Arbor, Ann Arbor, MI.

Abstract

https://ota.org/education/ota-online-resources/video-library-procedures-techniques/operative-management-atypical#/+/0/score,date_na_dt/desc/.

Dr. M. Hake is a consultant for Globus Medical. The remaining authors report no conflict of interest.

1. Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014;29:1–23.
1. Meier RPH, Perneger TV, Stern R, et al. Increasing occurrence of atypical femoral fractures associated with bisphosphonate use. Arch Intern Med. 2012;172:930–936.
1. Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90:1294–1301.
1. Bogdan Y. Atypical femur fractures. In: Tornetta P III, Ricci W, Ostrum R, et al., eds Rockwood and Green's Fractures in Adults. Vol 2. 9th ed. Wolters Kluwer; 2019:2341–2355.
1. Koh A, Guerado E, Giannoudis PV. Atypical femoral fractures related to bisphosphonate treatment: issues and controversies related to their surgical management. Bone Joint J. 2017;99-B:295–302.